 |
Corporate News
22-May-21
|
|
|
|
|
|
|
|
|
|
|
|
Natco Pharma receives USFDA approval for Lenalidomide Capsules
|
|
|
|
|
|
|
|
Natco Pharma announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, 5mg, 1 Omg, 15mg, and 25mg strengths, from the U.S. Food and Drug Administration (FDA), and the tentative approval of the 2.5mg and 20mg strengths.
NATCO, along with its marketing partner Arrow International (a U.S. affiliate of Teva Pharmaceutical Industries Ltd), previously settled the Paragraph IV litigation related to the product with Celgene (now part of Bristol-Myers Squibb), who sells the product under the brand-name REVLIMID®. NATCO and Arrow shall launch the product on
agreed-upon launch dates in the future.
|
|
|
|
Previous News |
Natco Pharma consolidated net profit rises 40.07% in the March 2024 quarter
(
Results
-
Announcements
28-May-24
12:05
)
|
|
|
Natco Pharma consolidated net profit rises 241.41% in the December 2023 quarter
(
Results
-
Announcements
15-Feb-24
16:17
)
|
|
|
Natco Pharma hits 52-week high as PAT rises 40% YoY in Q4
(
Hot Pursuit
-
28-May-24
10:58
)
|
|
|
Natco Pharma reports consolidated net profit of Rs 275.80 crore in the March 2023 quarter
(
Results
-
Announcements
29-May-23
15:39
)
|
|
|
Natco Pharma gains on buyback proposal
(
Hot Pursuit
-
03-Mar-23
09:29
)
|
|
|
Natco Pharma
(
Results
-
Analysis
14-Feb-22
21:40
)
|
|
|
Natco Pharma Ltd soars 2.4%, up for third straight session
(
Hot Pursuit
-
03-Mar-23
13:05
)
|
|
|
Natco Pharma announces board meeting date
(
Corporate News
-
03-Mar-23
10:46
)
|
|
|
Natco Pharma consolidated net profit rises 28.23% in the December 2021 quarter
(
Results
-
Announcements
15-Feb-22
08:15
)
|
|
|
Natco Pharma fixes record date for interim dividend
(
Market Beat
-
Reports
09-Aug-22
18:51
)
|
|
|
Natco Pharma to hold AGM
(
Corporate News
-
06-Sep-23
17:31
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|